New CRISPR Gene-Editing Therapy Shows Promise in Treating Severe Hypertriglyceridemia
A single-dose treatment successfully lowered triglyceride levels in a phase 1b clinical trial, marking a potential shift toward curative gene therapies.


PENN Explainer
Hear this story explained in 90 seconds.
A new gene-editing therapy has demonstrated significant success in reducing severely elevated triglyceride levels in a recent clinical trial. Researchers presented the findings from a phase 1b study at the American Heart Association Scientific Sessions 2026. The treatment, known as CTX310, uses CRISPR-Cas9 technology to edit the ANGPTL3 gene directly within the liver. This approach aims to address the root cause of severe hypertriglyceridemia rather than relying on long-term medication management.
The study involved a cohort of 10 patients who all suffered from the condition and had concurrent diabetes. Participants received a single infusion of the therapy to observe its impact on their lipid profiles. After 30 days, the mean triglyceride levels across the group dropped by approximately 63 percent. Lead investigator Ashish Sarraju, a cardiologist at the Cleveland Clinic, noted that the results signal a new frontier in drug development.
He explained that the findings represent the potential for a cure for patients who currently face the burden of chronic treatment. The therapy was generally well tolerated by the participants throughout the study period. No serious adverse events related to the drug were reported, and there were no concerning elevations in liver enzymes. Four patients experienced minor adverse events, but none were classified as severe.
The research team plans to continue monitoring the participants to ensure the long-term safety and durability of the gene-editing effects. This trial adds to a growing body of evidence supporting the use of in vivo CRISPR-Cas9 systems to treat complex genetic and metabolic disorders. As the field advances, scientists are looking toward larger trials to confirm these early, positive outcomes. The ability to perform precise genetic modifications inside the human body could eventually transform how doctors approach a wide range of chronic health conditions.
You've reached your free article limit
You've read 10 of 10 free articles this month. Subscribe to Planet Earth News Network for unlimited access to neutral, global journalism — plus puzzles, podcasts, and the weekly newsletter.
Already a subscriber? Sign in.
Ask the Author
Subscribers can ask the journalist a question about this story. Subscribe to ask.
Neutrality note
Auto-harvested from global news wires and presented neutrally by PENN.
to vote
Comments
No comments yet — be the first to share your thoughts.
Related stories in Science & Technology

New CRISPR Therapy Poised for Historic FDA Approval for In Vivo Gene Editing
2026-11-17
Scientists Discover Rare Star System Emitting Radio Signals Every Eight Minutes
2026-11-16
